Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding
Open Access
- 1 June 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 17 (6), 779-782
- https://doi.org/10.1016/j.jcf.2018.05.009
Abstract
No abstract availableKeywords
Funding Information
- NIH (T32 HL007106)
- CF Foundation (TRIMBL17A0)
- Cystic Fibrosis Foundation RDP (R026-CR11)
This publication has 11 references indexed in Scilit:
- Drugs during pregnancy and breast feeding in women diagnosed with Cystic Fibrosis - An updateJournal of Cystic Fibrosis, 2017
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delThe New England Journal of Medicine, 2017
- Pregnancy among cystic fibrosis women in the era of CFTR modulatorsJournal of Cystic Fibrosis, 2017
- A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic FibrosisJournal of Obstetric, Gynecologic & Neonatal Nursing, 2016
- A successful uncomplicated CF pregnancy while remaining on IvacaftorJournal of Cystic Fibrosis, 2016
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRThe New England Journal of Medicine, 2015
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)The Lancet Respiratory Medicine, 2014
- Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosisScience Translational Medicine, 2014
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- ATP suppression of interleukin‐12 and tumour necrosis factor‐α release from macrophagesBritish Journal of Pharmacology, 2000